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ABSTRACT 
PROFILE OF SYSTEMIC TREATMENT WITH THE ANTIVIRAL LECTIN 
GRIFFITHSIN IN GUINEA PIGS 
Christopher Lynn Barton 
May 25,2011 
Griffithsin (GRFT) is a carbohydrate binding protein derived from the red 
alga Griffithisia sp. that has been shown to effectively interfere with the cellular 
attachment and infectivity of a number of viruses, including HIV-1. However, it is 
currently unknown what impact systemic GRFT administration may have upon a 
biological system. For initial in vivo testing, we introduced GRFT into guinea 
pigs (Cavia Parcel/us) via subcutaneous injection. Based on histological, 
serological, and biochemical data derived from these experiments, GRFT is well 
tolerated and maintained at physiologically relevant concentrations while 
retaining its potent antiviral activity. Follow up in vitro testing included a number 
of assays to assess GRFT's interaction with serum proteins and proteases. The 
results confirm that GRFT is well tolerated by animals and maintains its antiviral 
activity while simultaneously displaying a strong resistance to proteolytic 
cleavage. Accordingly, GRFT is a strong candidate for further development as a 
systemic anti-viral therapy. 
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As the spread of viruses such as HIV, HCV, SARS and influenza 
continues throughout the world, it is imperative that new therapies are fully 
explored as potential weapons for stemming further transmission to uninfected 
individuals as well as treating those already infected. HIV, affecting 
approximately 33 million people worldwide, claims the lives of roughly 2 million 
people per year [1]. HCV, the most common blood born infection in the US, 
currently affects 3-4 million people, and is the leading cause of liver 
transplantation [2]. A common structural feature among all of these viruses is a 
dense, high-mannose N-linked glycan shield used to evade host immune 
responses and stabilize viral envelope structure [3-5]. Accordingly, agents that 
can target clusters of high-mannose glycans, typical of many viral envelopes, are 
highly attractive candidates for potential antiviral therapies. 
Among some of the most promising and potent topical anti-microbial 
agents currently being investigated to prevent transmission of HIV, HCV, SARS, 
and influenza are a subset of natural product derived lectins, carbohydrate 
binding proteins which bind to the envelope glycoproteins of many viruses, 
including HIV [6-9]. It is believed that these antiviral lectins can inhibit viral 
transmission by selectively binding to the N-linked mannose moieties present on 
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the suriace of the viral envelope, thus preventing viral entry [7, 10-12]. Griffithsin 
(GRFT), derived from the red algae Griffithisae sp., is one such lectin that is 
currently under investigation as a potential vaginal microbicide [13]. In vitro 
studies indicate that GRFT is a particularly potent HIV-1 entry inhibitor, with an 
average ECso of 40 pM [14]. 
In addition to direct binding activity on free virions, it has been 
demonstrated in vitro that antivirallectins, such as GRFT, can interiere with and 
prevent cell-to-cell transmission of HIV between dendritic cells and macrophages 
[13]. This ability to interiere with cell-to-cell viral transmission, as well as its ability 
to effectively bind to the GP120 of HIV viral particles, warrants an investigation 
into whether GRFT, in addition to its potential usage as a topical antimicrobial, 
has utility as a systemic treatment for HIV. 
The goal of this Master's thesis is to explore the potential of using GRFT 
as a systemic therapy for enveloped viruses possessing high mannose N-linked 
glycans by examining its systemic tolerability in guinea pigs, as well as 
investigating some of the biological interactions that GRFT may encounter during 
the course of systemic treatment. In Chapter 2, we assess GRFT's impact upon 
metabolic organ systems and examine GRFT's serum persistence and anti-viral 
activity when injected subcutaneously into guinea pigs. Chapter 3 explores 
biochemical interactions that GRFT may have when introduced into systemic 
circulation, including exposure to proteases and potential endogenous binding 
targets. Finally, in Chapter 4, we analyze a viral resistance profile in the context 
of HIV-1, examining glycosylation site changes that occur in a GRFT-resistant 
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HIV isolate. Also described is the process by which HIV-1 enveloped pseudovirus 
particles can be generated for examining GRFT's neutralization capacity. 
Glycosylation States 
Glycosylation is the process by which complex carbohydrate chains are 
enzymatically added to organic molecules, such as proteins and fats [15]. These 
carbohydrate chain additions serve as essential factors in maintaining proper 
protein folding, increase protein stability, and contribute to their functionality [16]. 
Furthermore, glycosylation can greatly affect the water solubility of proteins, 
given that the addition of the carbohydrate chains results in greater hydrophilicity. 
In the case of viruses, glycosylation changes of external proteins and lipids can 
greatly impact infectivity and viral fitness [17]. 
Occurring in either the golgi apparatus or the endoplasmic reticulum, 
glycosylation can result in five different types of glycans: N-linked, O-linked, C-
linked, glipiated, or phospho-glycans. The type of glycosylation most relevant to 
the studies of GRFT are of the N-linked variety. Beginning with the addition of a 
14 unit oligosaccharide precursor to an asparagine in a polypeptide chain, N-
linked glycosylation is signaled by either the sequence Asn-X-Ser or Asn-X-Thr, 
where X can be any amino acid except proline [18]. As a structural precursor 
common to most eukaryotes, the general branched carbohydrate chain contains 
3 glucose, 9 mannose, and 2 N-acetylglucosamine molecules. Subsequently, 
this branched carbohydrate chain is attached to a carrier molecule called a 
dolichol, and transferred to the appropriate signal sequence (NXSfT) on the 
polypeptide chain as it is translocated into the ER lumen [19]. 
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In addition to the varying linkage types available for glycosylation, there 
are also differences in sugar compositions between glycans of the same linkage 
type. These differences can result in the following sub-types of glycans: High-
mannose, Hybrid, or Complex (Fig.1.1). These different subsets vary in the 
amount of n-acetylglucosamine presented on the terminal portions of the sugar. 
Whether an oligosaccharide will ultimately be High-mannose, Complex or Hybrid 
is thought to depend on its accessibility to saccharide-modifying proteins in the 
Goigi. High-Mannose glycans are a type of the N-glycan chain added to certain 
asparagine residues of secreted or membrane proteins in eukaryotic cells, 
containing 5-9 mannose residues [15]. High-mannose glycans are the initial 
state of glycosylation for many glycans, with further editing occurring in the Goigi 
which results in the formation of hybrid and complex glycans. 
The final, terminal structure of the glycan after editing determines its 
subtype. In the case of High-mannose glycans, no n-acetylglucosamines are 
presented, resulting in exclusively mannose terminals (Fig. 1.1 A). In the case of 
Hybrid glycans, enzymatic activity results in a carbohydrate chain that possesses 
at least one terminal N-acetylglucosamine and at least one terminal mannose 
(Figure 1.18). However, in the case Complex N-linked glycans, enzymatic 
activity results in a carbohydrate chain containing multiple terminal N-
acetylglucosamines (Fig.1.1 C). Deficiencies in certain key modification 
enzymes can greatly affect glycosylation profiles. For example, reduction in 
activity of cellular N-acetylglucosaminyltransferase I (GnT -I) - a glycan editing 
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enzyme - can result in the production of almost entirely High-mannose type 
glycans [20]. 
HIV-1 
HIV-1, the virus responsible for AIDS, is a lentivirus belonging to the 
retrovirus family of viruses [21]. Genetically, the HIV genome contains a total of 
nine genes which can code for a number of viral proteins [22]. Three of them 
encode structural and functional proteins essential for new virons: Gag, Pol, and 
Env [22]. These three genes code precursor proteins which must be further 
processed by cleavage before they become functional. Six other genes- tat, rev, 
nef, vif, vpr and vpu-code for various viron processing mechanisms, including 
cellular transport, assembly, and budding [22]. 
Gag encodes a precursor protein which is cleaved into four proteins: 
matrix (p17), capsid (p24), neocapsid (p7), and p6 proteins [22]. This group is 
synthesized as the p55 polyprotein which is subsequently cleaved by viral 
protease into their individual components as well as two spacer proteins, p1 and 
p2 [22]. These individual proteins are involved in viron core structure, assembly, 
and budding. 
Pol genes also code for the synthesis of a single unit precursor protein 
which is cleaved to produce viral protease, reverse transcriptase and integrase 
[22]. These proteins are packaged with new virons and are necessary for proper 
viral protein function, cDNA synthesis, and cDNA integration into the host 
genome [22]. 
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The Env glycoprotein, which consists of gp120 and gp41, is also 
synthesized as a 160kDa glycoprotein precursor protein which requires cleavage 
into its individual proteins [22]. A signal peptide sequence on gp160 signals for 
ER trafficking and post-assembly modification and glycosylation. After 
modification, gp160 is cleaved into gp120 and gp41 by a furin-like protease [22]. 
From there transmembrane protein gp41 proteins are assembled into Env trimers 
with gp120 molecules [22]. 
Two main proteins of interest in relation to lectin inhibition of HIV-1 are 
gp41 and gp120. The outer viral envelope of HIV consists of phospholipids taken 
from the host cell, whereas gp41 and gp120, encoded by the env genes of HIV, 
form the viral envelope spike [23]. Structurally, gp120 trimers associate with 
GP41 trimers in a non-covalent manner to form the envelope spike [23]. This 
spike then interacts with the CD4 receptor present on target cells as well as 
either the CCR5 or CXCR4 co-receptor molecules to initiate cellular infection 
(Fig. 1.2) [24-27]. 
HIV Course of Infection 
The functional course of viral infection of a susceptible T-cell follows a 
characteristic pathway. First, gp120 present on the envelope of HIV binds with 
the CD4 receptor molecule, which normally assists with the activation of T -cells 
upon interaction with an antigen presenting cell (Fig. 1.2) [24, 28-29]. Upon 
binding, the core of the gp120 trimer undergoes conformational changes, 
resulting in greater flexibility and interaction with either the CCR5 or CXCR4 co-
receptor, which are necessary for further steps in viral fusion [30-32]. Following 
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co-receptor engagement, a conformational change occurs in the envelope spike, 
altering the state of gp41 [33-34]. This conformational change allows the n-
terminal domain of gp41 to become exposed and inserted into the cellular 
membrane [33]. Finally, this insertion induces a final structural change causing 
the formation of a six-helix bundle, which provides the force necessary for 
cellular fusion [33-35]. 
Upon successful cellular fusion, the capsid releases two copies of RNA as 
well as the accessory molecules necessary for replication - reverse 
transcriptase, integrase, and viral protease. Reverse transcriptase converts the 
RNA copies to DNA [22]. Integrase functions to cleave the host DNA, integrating 
the viral DNA into the host cell's genome [22]. Viral protease serves to cleave 
precursor polyproteins into their functional units [22]. 
The mechanisms of productive systemic infection can vary somewhat by 
point of entry. In HIV-1 transmission following mucosal exposure, cellular binding 
of the viral particle to a susceptible cell is the first step in the process of HIV 
infection It has recently been come to be understood that successful infection 
often is accomplished by HIV isolates which have more compact variable loops 
of gp120, with reduced numbers of N-linked glycans [36] . These viral particles 
infect suboptimally activated memory CD4+ T cells in the genital mucosa [37-39]. 
Following low level replication, HIV-1 infects fully activated CD4+ T cells, leading 
to migration of the virus to gut-associate lymphoid tissues where viral replication 
is further amplified [40-41]. This leads to a high level viremia that establishes 
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acute infection as well as a depletion of gut-associated T-cells possessing the 
a4~7 gut homing integrin [36]. 
Vaginal transmission is the most common route of transmission 
worldwide, as the majority of HIV-1 infected individuals worldwide are women. It 
is believed that the cervix, which has a less protective columnar epithelium and is 
rich in HIV-1 target cells, is a major site for HIV-1 transmission[42-44]. After 
sexual intercourse, this area is exposed to seminal fluid, allowing contact 
between virions and susceptible cells. 
Receptive anal intercourse provides the greatest probability of mucosal 
transmission [45-46]. This is likely due to two factors; a fragile layer of columnar 
epithelium that can be damaged by the virus, and a high level of constitutively 
activated T lymphocytes in the gut epithelium [45,47-49]. However, even in the 
absence of epithelial damage, HIV-1 transmission in the anal mucosa can occur 
through transcytosis or through infection of dendritic cells [50-51]. 
During penile transmission occurring during sexual intercourse, the route 
of infection likely occurs via either the inner foreskin or through the penile urethra 
[52-53]. The inner foreskin has abundant levels of HIV-1 target cells, including 
CD4+ T cells, macrophages, and Langerhans cells [52]. Furthermore, the penile 
urethra also has a population of CD4+ T cells and macrophages [52]. Thus, 
during sexual intercourse, these surfaces become exposed to infected fluids, 
exposing vulnerable tissues to potential infection. 
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GP120 structure and glycosylation 
As a protein produced by its eukaryotic host cells, the gp120 protein of 
HIV is highly glycosylated, with an average of 24 glycosylation sites [54]. Recent 
studies have shown that the glycosylation state of gp120 consists almost entirely 
of the high-mannose variety [20]. It is currently hypothesized that this is due to 
the inability of host editing proteins and a mannosidases to access the glycans 
effectively, resulting in the inability to modify high mannose glycans into a hybrid 
or complex form [20]. 
As with similar proteins, gp120 N-linked glycosylation relies on the signal 
triplet Asn-X-Ser or Asn-X-Thr for the addition of the carbohydrate chains. 
However, given the low fidelity of the HIV reverse transcriptase, there can be 
great diversity in the number of high mannose glycans present on gp120 as the 
virus evolves to avoid host defense mechanisms. Some studies have shown that 
an increase in potential N-linked glycosylation sites can result in increased viral 
fitness by reducing sensitivity to host produced neutralizing antibodies by 
obscuring binding sites recognized by antibodies [55]. 
However, other studies have shown that decreases in glycosylation sites 
may also playa role in viral fitness and infectivity. Studies of sequence data has 
demonstrated that viral particles in a newly infected host have fewer 
glycosylation sites as well as shorter variable loops [56-57]. These changes are 
believed to facilitate the binding of the virus to the host receptor cells without the 
interference by the carbohydrate chain additions. However, as the virus begins 
replicating and is placed under neutralizing antibody pressure, an increase in 
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glycosylation sites is observed. Accordingly, additions of glycosylation sites in 
the gp120 may promote viral fitness in successive replication cycles by allowing 
the virus to evade neutralizing antibodies by denying them access to previously 
recognized epitopes. 
Antiviral treatments 
Many different pharmacological strategies and drugs are currently in use 
for the treatment of HIV. These drugs include non-nucleoside reverse 
transcriptase inhibitors, nucleoside reverse transcriptase inhibitors, protease 
inhibitors, integrase inhibitors, and fusion inhibitors. These therapies have 
greatly increased the ability of an HIV infected individual to live close to a normal 
life span. Prior to the advent of Highly Active Anti-Retroviral Therapy (HAART), 
the expected survival span of an individual infected with HIV was 5 to 10 years. 
Today, the life expectancy of a 20 year old starting antiretroviral therapy is an 
additional 49 years [58]. The goal of HAART is to preserve immune function, 
extend survival time, as well as suppress viral load to undetectable levels. 
However, the complete elimination of HIV in those already infected seems 
unlikely, if not impossible, due to the establishment of viral reservoirs within the 
body which maintain a base level of infection, even while viral loads are deemed 
undetectable. It is theorized that these viral reservoirs are the result of a latent 
infection of long lived cells, or a suppressed but continual low level viremia in 
which active cell to cell transmission continues to occur, or a combination of both 
of those factors [59-63]. Accordingly, an agent that could further prevent cell-to-
cell transmission of HIV, and thus assist in reducing or eliminating viral 
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reservoirs, would be an attractive complementary treatment to those whose viral 
loads are suppressed to undetectable levels. 
Entry Inhibitors 
Among some of the newest agents currently being investigated as a 
treatment of these viruses are entry inhibitors that can prevent viral fusion with its 
target cell at various phases of the viral entry process. Entry inhibitors can act in 
a number of ways, including presenting a physical barrier to viral fusion by 
binding to the virus to prevent infection or by altering the cellular receptors 
necessary for viral infection [13, 64]. Entry inhibitors can currently target a 
number of proteins on either the virus or the cell. These targets include gp120 or 
gp41 of HIV virions, the C04 receptor present on T-cells, or the CCR5 or CXCR4 
co-receptors present on C04 cells. 
T20, or Enfuvirtide, is an injectible peptide fusion inhibitor [65]. Enfuvirtide 
is commonly used as part of a combination therapy when other therapies have 
failed. Enfuvirtide acts by binding to gp41, preventing conformational changes 
that are necessary for successful cellular infection (Fig. 1.20) [34]. As a 36 
amino acid peptide, it mimics the HR2 fragment of gp41, and binds to the HR 1 
region of gp41 [66-67]. Binding to the H1 region thus blocks formation of the six 
helix bundle, the primary driving force for the final steps of cellular fusion process 
[34]. In 2003, enfuvirtide was approved for treatment of HIV infection, due to 
virological benefits seen when added as an adjunct antiretroviral regimen [68]. 
Maraviroc is a small molecule, CCR5 co-receptor antagonist, which is also 
used as an entry inhibitor in the treatment of HIV-1 [69-71]. Maraviroc 
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allosterically binds to the transmembrane cavity of the CCR5 co-receptor, thus 
blocking its interaction with gp120 after gp120 has bound to the CD4 receptor 
(Fig. 1.2C) [72]. This prevents subsequent binding steps and conformational 
changes necessary for viral fusion with the cell. 
Ibalizumab is a CD4-targeting antibody that is currently being examined as 
an entry inhibitor [73-75]. While non-immunosuppressive, Ibalizumab binds the 
CD4 molecule present on T -cells in the D2 region of the receptor (Fig. 1 .2A) [76-
77]. This binding prevents conformational changes in the CD4 receptor 
necessary for later steps in cellular infection. However, it does not interfere with 
either the binding of MHC II molecules or the gp120 to the receptor, and thus 
does not interefere with normal immune function [76-78]. 
One class of potential entry inhibitors are a subset of lectins, carbohydrate 
binding agents. Generally, lectins are highly specific sugar binding proteins 
which can agglutinate cells or precipitate conjugated sugars. Lectins can serve a 
variety of purposes in plant and animal cells. In animals, they can serve to 
regulate cell adhesion and by recognizing carbohydrates exclusively present on 
pathogens. For example, mannose binding lectin is a serum protein which plays 
a role in innate immunity by binding to pathogens, resulting in activation of the 
complement system or opsonization of the pathogen [83]. 
Antivirallectins are a subset of lectins which bind to the envelope glycans 
of many viruses, including HIV and HCV [7]. This subset includes Concanavalin 
A, Cyanovirin, and Actinohivin [12, 79-80]. While different lectins have different 
carbohydrate targets, it is believed that antivirallectins effective against HIV 
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infection inhibit viral transmission by selectively binding to the N-linked high-
mannose glycans present on the surface of the trimeric gp120 spike, thus 
preventing cellular fusion (Fig. 1.28) [7]. It has also been theorized that cross-
linking and aggregation of viral particles may also be an additional and equally 
vital mechanism of viral inhibition [81]. 
Despite their promise as potential neutralizing agents for HIV and HCV, 
lectin treatment can present a challenge. Aside from potential side effects due to 
mechanism of drug action, the presence of proteinaceous drugs can induce 
allergic reactions and anaphylaxis. As foreign proteins, there is no opportunity 
for central tolerance to their sequences to develop within immature T and 8 cells. 
Accordingly, exposure to the protein can activate T and 8 cells, initiating an 
immune reaction [82]. However, immune reactions can vary. Neutralizing 
antibodies can also be generated which effectively bind the protein and facilitate 
its degradation [82]. However, it is also possible that type I immediate 
hypersensitivity reactions can be initiated which result in anaphylaxis [82]. 
Anaphylaxis is a potentially deadly reaction to immunogens wherein mast cells 
are degranulated by the binding of IgE [82]. Multivalent binding of IgE to antigen 
results in cross linking of FcRe, which activates degranulation [82]. This 
degranulation results in the release of large amounts of histamine and TNF-a 
[82]. 
Anaphylaxis has been observed in a number of proteinaceous drug 
treatments. These drugs include Omalizumab, a monocolonal antibody 
treatment for asthma, alpha galactosidase A for the treatment of Fabry's disease, 
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and Rituximab for the treatment of leukemias and autoimmune disorders [83-86]. 
Fortunately, interventions can be used to delay and mitigate reactions to foreign 
proteins. For example, treatment with methotrexate can delay immune response 
to a-Galactosidase A therapy [87]. By depressing certain immune function, the 
numbers of activated and replicating immune cells is decreased, resulting in a 
decrease in potential production of antibodies. Nonetheless, as effective protein 
therapies are employed, a full understanding of the potential immunological 
consequences of drug administration will be valuable in devising strategies to 
avoid such immune responses. 
Griffithsin Structure and Mechanism of action 
GRFT is a carbohydrate binding agent with high affinity for N-linked high 
mannose glycans [13-14]. In solution, GRFT forms a domain swapped 
homodimer with a total of 6 mannose binding sites, as determined by X-ray 
crystallography of GRFT at 1.3A resolution [88-89]. Structural complexes of 
GRFT with both man nose and N-acetylglucosamine have defined locations of 3 
virtually identical carbohydrate binding sites on each monomer which use a 
highly conserved GGSGG motif found in the loops of the protein [90]. This 
sequence, as well as a dimeric domain swap forming the third binding pocket on 
each side, provides amide groups which form the ligand binding sites. Upon 
dimerization, GRFT's binding sites form an almost equilateral triangle on the 
edge of the protein, creating two opposing surfaces for man nose binding [88]. 
GRFT's anti-HIV inhibitory capacity is mediated through its binding to the 
high-mannose glycans present on the gp120 spike of HIV [14]. This binding 
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interaction thus becomes a barrier to infection by preventing interaction between 
the viral gp120 and the CD4 molecule of its target cells. Supporting this theory is 
the fact that lectin-resistant isolates of HIV have been generated in the laboratory 
by placing HIV under increasing concentrations of GRFT over successive 
passages [4]. A genomic analysis of the envelope glycoproteins of these isolates 
reveals that a number of glycosylation sites in the resistant viruses were deleted, 
thus decreasing the number of potential binding sites for lectin activity. 
To determine whether systemic effects of GRFT are the result of the 
active site of GRFT or simply by the presence of foreign proteins, we have 
developed a mutated form of the drug, GRFT1ec-, in which the carbohydrate 
binding sites have been ablated by amino acid substitution (a substitution of 
asparagine for aspartic acid residues in the binding pockets). While structurally 
similar to mannose-binding GRFT in structure and sequence, this mutated form 
does not bind high man nose glycans and demonstrates no antiviral activity in 
pseudovirus challenges. 
In order for GRFT to be a viable systemic antiviral treatment, it must be 
able to be efficiently and economically produced, maintained in blood serum at 
safe and therapeutic levels, and retain its anti-viral activity in the systemic 
circulation. Prior work has demonstrated that GRFT is able to be efficiently and 
economically produced in large quantities [91-92]. Additionally, prior studies 
have demonstrated GRFT's weak immunogenicity and low induction of 
inflammatory cytokines and chemokines[13, 92]. However, little study has yet 
been conducted into the systemic tolerability of GRFT or the retention of its anti-
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viral activities in vivo. Furthermore, given that HIV is known to acquire drug 
resistance when placed under drug pressure, insight is needed into the molecular 
interactions that result in GRFT-resistant isolates. 
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c 
II 13-1,4 GIcNAc 
e 13-1,4 Mannose 
e a-l,6 Mannose 
0 a-l,3 Mannose 
e a-l,2 Mannose 
e 13 -1,2 GIcNAc 
13 -1,4 Galactose 
Figure 1.1. N-linked glycans - structural arrangement of subtypes. Schematic 
depicting examples of different types of N-linked glycans. High Mannose glycans 
(A) present exclusively mannose termini. Hybrid glycans (8) present a mixture of 
mannose termini and GlcNac termini. Complex glycans (C) are devoid of 
mannose termini. 
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1. CD4 Receptor 
Attachment 







Figure 1.2. Steps of HIV-1 cellular entry highlighting sites of potential therapeutic 
interventions. The above schematic demonstrates the steps of HIV-1 entry 
relevant to different entry inhibitors including C04 attachment, co-receptor 
binding, and cellular fusion. Potential therapeutic intervention points include: (A) 
Ibalizumab binding site on the C04 molecule to prevent C04 conformational 
changes necessary for co-receptor binding, (8) lectin binding sites for glycans 
present on gp120 to prevent proper C04 interactions, (C) Maraviroc (CCR5 
antagonist) binding site to prevent gp120/co-receptor interaction, and (0) 
Enfuvirtide (T20) binding site to prevent conformational changes in gp41 
necessary for the final stages of cellular fusion . 
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CHAPTER 2 
ASSESS GRFT'S SHORT TERM SYSTEMIC TOLERABILITY, ANTI-VIRAL 
ACTIVITY, AND SERUM PERSISTENCE IN THE ABSENCE OF AN ANTIBODY 
RESPONSE 
INTRODUCTION 
In this Chapter we will examine the systemic effects that subcutaneously 
injected GRFT has upon the systemic physiology of female guinea pigs (Cavia 
porcel/us). Given GRFT's demonstrated ability to block cell to cell transfer of 
HIV-1, it is important to fully investigate any short term toxicological impacts that 
GRFT has on a living system's physiology. Due to an inherently low background 
HIV neutralizing activity in serum and blood, guinea pigs were chosen for the 
animal model in this study so as to allow for full evaluation of GRFT's continued 
neutralizing capacity after systemic introduction. 
Given that the introduction of a foreign protein into a living system will 
expose said protein to a vast number of proteases and potential degradatory 
pathways, it was important to ascertain whether GRFT would: 1. maintain its 
stability in serum; 2. maintain its anti-viral activity in an environment in which 
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endogenous high mannose binding may occur; and 3. distribute into particular 
organs or tissues. 
For the experiments described in this chapter, GRFT, GRFr1ec-, or PBS 
was injected subcutaneously into guinea pigs for a period of ten days. Drug 
effects on Complete Blood Counts (CBC's), normalized organ weights, body 
weight, and select serum chemistries were monitored for any changes in 
experimental groups relative to PBS-treated controls. Additionally, histological 
analysis of kidneys, spleens, livers, and vaginas was carried out on all animals to 
document treatment associated pathologies as well as to determine whether 
pathologies were due to protein presence or drug action. Finally, 
hemagglutination assays were conducted to evaluate whether GRFT, as a lectin, 
has the ability to cause erythrocyte aggregation. Potential aggregation of 
erythrocytes could cause potential increases in red blood cell turnover, as well as 
possibly make GRFT unable to be used in systemic circulation. 
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MATERIALS AND METHODS 
Twenty-six (26) female Hartley guinea pigs (Charles River), ranging from 
6-8 weeks of age were chosen as the animal model given their low anti-HIV 
neutralizing background in blood and serum. Six groups were formed, 
consisting of 6 PBS treated animals (Groups 1 a and 1 b), 10 GRFT-treated 
animals (Groups 2a and 2b) and 10 GRFT1ec- treated animals (Groups 3a and 
3b). 
Injection and Dosage 
GRFT, manufactured by Kentucky Bioprocessing, LLC, was diluted in 
Phosphate Buffered Saline (PBS, pH 7.4) to achieve a final concentration of 
10mg/ml. GRFT1ec-, already at 9.5mg/ml, required no dilution before 
administration. Subcutaneous injections of the appropriate drug solution or 
vehicle (PBS) were conducted daily for a period of 10 days. Control group 
members were injected with 1 ml/kg/day PBS, while animals from test groups 2 
and 3 received doses of 1 Omg/kg/day of GRFT or GRFT1ec-, respectively. For 
dosage determination and adjustment, all animals were weighed on days one 
and five. 
Sample collection 
Group members from 1 a, 2a, and 3a were weighed and euthanized twenty 
four (24) hours after last treatment. All remaining group members were weighed 
and euthanized 96 hours later. Euthanizations via cardiac puncture 
exsanguination were performed under isoflurane anesthesia, followed by 
thoracotomy. Vaginal lavage samples for Groups 1a, 1 b, 2a, and 2b were taken 
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via pipette using PBS prepared with 1 x Protease Arrest and EDTA (G 
Biosciences) to prevent proteolytic degradation of GRFT. Kidneys, livers, 
spleens, and vaginas were excised, weighed, and fixed in 10% formalin for 48-72 
hours. After fixation, organs were placed in 70% ethanol and sent for slide 
preparation, hematoxilin & eosin staining, and histological analysis. 
Measurement of GRFT Concentrations 
Serum was collected from blood samples by centrifugation and 
concentrations of active GRFT were determined using a GP120 sandwich ELISA. 
Briefly, 96-well Maxisorp plates were coated with 100 III gp120 diluted in PBS, at 
a concentration of 250 ng/ml. After overnight incubation at 4*C, and subsequent 
blocking of the plate wells with 3% BSA in 1xPBS-T, serum samples were 
diluted (1: 10) in blocking buffer and incubated in the 96-well plate at room 
temperature for one (1) hour. After washing in PBS-T, polyclonal rabbit anti-
GRFT primary antibody (1 :25000 dilution in blocking buffer) was incubated for 1-
2 hours. After a second cycle of PBS-T washes, wells were incubated with a 
HRP-conjugated goat anti-rabbit secondary antibody (1 :10000 dilution in blocking 
buffer) for one hour. Following the one-hour incubation, wells were washed,and 
100 III of SureBlue TMB Microwell Peroxidase substrate was added to each well 
and developed in the dark for 10 minutes. The addition of 100 III of 1 N sulfuric 
acid was used to stop the reaction. Absorbance readings at 450 nm and 570 nm 
were measured using a BioTek Synergy HT plate reader. 
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Concentrations of GRFT1ec-
GRFT1ec- concentrations were not amenable to detection via gp120 
sandwich ELISA given the inability of GRFT1ec- to bind to gp120. Accordingly, we 
attempted to detect GRFT1ec-presence by SDS PAGE and Western blot. Serum 
drawn from GRFT-treated guinea pigs and serum drawn from GRFT1eC--treated 
guinea pigs were diluted 1:1 in sample buffer and separated by SDS PAGE on 
an anyKD readygel (Biorad) for 20 minutes at a constant 200 volts. Transfer to 
PVDF membrane was accomplished using a transfer buffer of 10% Methanol, 
10mM N-cyclohexyl-3-aminopropanesulfonic acid (CAPS) buffer. Transfer was 
carried out at 200v for 25 minutes. After transfer to PVDF, the membrane was 
blocked using a blocking buffer consisting of 5%non fat dry milk (NFDM) in PBS. 
GRFT and GRFT1ec-presence was evaluated by incubating the membrane in a 
rabbit anti-GRFT primary antibody (diluted 1 :25000 in blocking buffer) for one 
hour at room temperature. Following primary antibody incubation and rinsing in 
PBS-T, the membrane was incubated in a goat anti-rabbit HRP-conjugated 
secondary antibody (diluted 1:10000 in blocking buffer) for one hour at room 
temperature. The membrane was washed in PBS-T and chemiluminscence was 
detected by exposure of the PVDF membrane to X-ray film after addition of HRP 
substrate. 
Anti-HIV Activity 
The anti-HIV activities of serum and vaginal lavage samples were 
measured by our collaborator at Duke University, David Montefiori using a 
pseudovirus neutralization assay. Antiviral activity was measured as a reduction 
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in luciferase reporter gene expression as previously described[93]. 1050 values, 
which represent antiviral activity, were reported as sample dilutions at which 
relative luminescence units (RLUs) were reduced 50% compared to virus control 
wells containing no serum or vaginal lavage sample. Virus stocks of molecularly 
cloned Env-pseudovirus of Ou156.16 were prepared by transfection of 293T cells 
and were titrated in TZM-bl cells as previously described. [93] 
CBC and Serum Chemistry 
At sacrifice, blood drawn via cardiac puncture exsanguination was 
aliquotted into vials containing EOT A for complete blood count (CBC) analysis. A 
complete CBC profile for each guinea pig in the control and GRFT-treated groups 
was generated. Briefly, 20 III of whole blood was loaded into a Hemavet 950FS 
and run according to manufacturer's directions. The CBC profile included 
examination of the following: White blood cells (WBC), Neutrophils(Ne), 
Lymphocytes (Ly), Monocytes (Mo), Eosinophils (EO), Basophils (Ba), Red Blood 
Cells (RBC), Hemoglobin (Hb), Hematocrit (HCT), Mean Corpuscular Volume 
(MCV), Mean Corpuscular Hemoglobin (MCH), Mean Corpuscular Hemoglobin 
Concentration (MCHC), Red blood cell distribution width (ROW), Platelet and 
Mean Platelet volume (MPV). Based upon the results of a pilot study on the 
effects of GRFT on guinea pig serum chemistries, three serum chemistry profiles 
were analyzed: serum albumin (Alb), alkaline phosphatase (ALKP), and amylase 
(Amy). Serum samples from all treated animals was obtained as described 
previously and tested for the selected chemistry values. 
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Immunofluorescent Imaging 
GRFT presence in unstained, formalin fixed tissue slide was visualized by 
immunofluorescent detection. Organ slides were deparaffinized and hydrated by 
duplicate and successive 10 minute incubations in Histoclear, 100% ethanol, and 
95% ethanol. Slides were then subjected to antigen retrieval by immersion in 
1 mM sodium citrate buffer and high pressure heating using a 2100 Retriever 
antigen retriever. Following a 10 minute PBS wash with agitation, slides were 
blocked with 5% goat serum (v/v) in PBS for 15 minutes. Slides were then 
incubated with polyclonal rabbit anti-GRFT primary antibodies at 1 :100 dilution in 
blocking buffer for one (1) hour. After washing in PBS, slides were incubated for 
one hour with a FITC-conjugated goat anti-rabbit secondary antibody at a 1 :500 
dilution. After final incubation, slides were washed twice in PBS for 10 minutes 
per wash. Slides were cover-slipped with Prolong Gold Anti-fade reagent with 
DAPI . Slides were then imaged at 200x magnification using an Olympus CKX41 
microscope and the appropriate fluorescence filter. 
Hemagglutination 
Hemagglutination activity of GRFT was evaluated. To test GRFT's 
hemagglutination activity guinea pig erythrocytes (Innovative Research) were 
washed with PBS to remove cell debris. Cell suspensions were spun down at 
1000 x g for one minute and resuspended at a final cell concentration of 1-2% in 
PBS containing 3 giL BSA and 1 giL sodium azide. Serial dilutions of either 
Phytohemagglutinin (PHA) (positive control) or GRFT were mixed with an equal 
volume of erythrocytes in a 96 well round bottom plate (total 100 IJUwell) and 
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incubated for 1 hr at room temperature, followed by overnight incubation at 4*C. 
Plates were then allowed to dry. Hemagglutination activity was determined by 
visual examination of erythrocyte aggregation or dissemination versus controls, 
with hemaggutination activity indicated by dissemination of blood cells in the 
entire well as opposed to collection of blood cells into a single point. 
Statistical Analysis 
Statistical analysis was conducted using the Graph Pad Prism 5 program. 
Groups were split between time points of day 11 (24 hour) results and day 15 
(120 hour) results, reflecting date of euthanization. ANOVA was performed for 
weight changes, organ weight differences, and serum chemistries between time-
matched groups. For the analysis of CSC data, for which GRFTlec• data was not 
collected, t-tests between time-matched Control and GRFT-treated groups were 
used. A p-value of <0.05 was deemed significant. 
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RESULTS 
Animal Morbidity and Mortality Observations 
No animals were lost during the treatment period. No unusual behavior 
during the treatment period was noted. 
GRFT Serum Blood concentration 
GRFT-treated animal sera contained measurable concentrations of GRFT 
24 and 120 hours after last treatment. GRFT concentrations detected in serum 
via a GP120-binding ELISA were plotted against their applicable test group (Fig. 
2.1). PBS-treated control groups 1 a and 1 b showed no GRFT presence. Day 
11-group 2a displayed an average GRFT concentration of 36 nM. Day 15-group 
2b displayed an average serum GRFT concentration of 11.36 nM. 
GRFT1ec- Serum Blood concentrations 
GRFT1ec- was not detected by Western blot in serum from groups 3a and 
3b (Img. 2.1). Serum from groups 2a and 2b were run in parallel, with GRFT 
detected in those samples. Purified GRFT1ec- was run as a control to ensure that 
the rabbit polyclonal antibody could detect the mutated form of GRFT. As 
expected, a band was observed at 12.7 kDa. 
GRFT Vaginal Wash Concentrations 
Concentrations of GRFT in vaginal lavage samples were determined by 
gp120-binding ELISA (Fig. 2.1). GRFT -treated animals displayed measurable 
concentrations of GRFT in vaginal wash samples at both 24 and 120 hours after 
last systemic administration, however GRFT was not detected in vaginal lavage 
samples from PBS-treated animals. Vaginal washes from Group 2a animals 
27 
displayed an average detectible GRFT concentration of approximately 9 nM. 
Furthermore, vaginal washes from Group 2b animals continued to display 
detectible GRFT concentrations of 2 nM. 
Anti-HIV Activity 
Antiviral activity was quantified using serum and vaginal wash samples of 
animals treated with GRFT. HIV env-pseudovirus neutralization assays revealed 
that GRFT retains its anti-HIV activity while in serum. Anti-viral activity was 
plotted against the group from which serum was collected (Fig. 2.2). ID50 values, 
representing anti-viral activity, were reported as the sample dilution at which 
relative luminescence units (RLUs) were reduced 50% compared to virus control 
wells containing no test sample. Sera from PBS-treated control groups displayed 
a mean neutralization activity of less than 20. Sera from GRFT-treated animals in 
Group 2a displayed a mean HIV neutralization capacity of 3277. Serum samples 
from GRFT-treated animals in Group 2b displayed an average neutralization 
activity value of 576. 
Vaginal wash samples also displayed measureable anti-HIV activity, 
however at much lower levels than those found in serum. Vaginal wash samples 
from Group 2a were deemed to have a mean neutralization capacity of 
approximately 70, whereas samples from Group 2b possessed a mean 
neutralization capacity of approximately 40. 
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Guinea Pig CBCs 
No significant differences were observed on either day 11 or day 15 in the 
numbers of the following categories: White Blood Cells, Neutrophils, 
Lymphocytes, Monocytes, Eosinophils, Basophils, Red Blood Cells, Hemoglobin, 
Hematocrit, Mean Corpuscular Hemoglobin, Mean Corpuscular Hemoglobin 
Concentration, Platelets, or Mean Platelet Volume (Table 2.1). However, Group 
2b red blood cell distribution width (ROW) and Mean Corpuscular Volume (MCV) 
values were significantly different. Despite the statistically significant difference 
in ROW values, all values for ROW were within normal physiological range for 
guinea pigs, according to normal ranges for guinea pigs coded within the 
Hemavet 950FS programming. 
Alkaline Phosphatase, Amylase, and Albumin. 
Analysis of serum chemistries revealed significant differences in serum 
albumin and amylase levels on day 15 (120 hours post treatment). Bonferroni 
post test comparisons between treatment groups vs. controls revealed that the 
differences seen in ANOVA analysis were attributable to differences observable 
in GRFT'ec- treated groups, which were significantly lower than controls. 
Animal weight gain 
Analysis of animal weight gains during treatment revealed differences in 
percentage weight gain between groups. Animals in groups 2a (GRFT-treated) 
and 3a and 3b (GRFT,eC-treated) experienced significantly less weight gain than 
time-matched PBS controls. Animal percentage weight gain during treatment 
was calculated and separated by sacrifice day and test group (Fig. 2.3). On day 
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11, Group 1 a control animals had experienced substantially greater weight gain 
than both GRFT and GRFT1eC--treated groups (groups 2a and 3a). Furthermore, 
GRFT1eC--treated animals in Group 5 continued to display significantly less weight 
gain in comparison to PBS-control group 1 b. However, group 2b no longer 
displayed a statistically significant difference when compared against controls 
when analyzed by Bonferroni post hoc test. 
Organ weights 
Liver, kidney, and spleen weights at time of sacrifice were analyzed for 
significant change in relation to total body weight. Average organ weight- to-
body weight percentages were plotted against test groups (Fig. 2.4). Liver 
weights showed no significant difference on either day 11 or day 15. Results for 
kidney weight were mixed, with no difference observed at day 11. However on 
day 15 there was a significant difference amongst groups observed when 
analyzed by two-way ANOV A. A Bonferroni post test between test groups vs. 
control was conducted, showing a significant difference control and GRFT1ec-
treated groups. Spleen weight difference results were also mixed, with no 
significant difference observed at Day 11. However, on day 15, G RFT -treated 
groups displayed a statistically significant greater spleen to body weight ratio 
when analyzed by ANOVA and Bonferroni post test. 
Organ Histopathology and Imaging 
Although there were diverse pathologies observed among all treatment 
groups, no pathologies related to GRFT treatment were observed. Among all 
treatment groups, notable pathologies included chronic pyelitis in the kidneys, 
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extramedullary hematopoesis localized in the spleen, and a minimal or mild 
chronic portal or periportal hepatitis in the livers. 
Immunofluorescent Imaging 
Immunofluorescent imaging of organ sections revealed a strong presence 
of G RFT in G RFT -treated animals both 11 days and 15 days after treatment in 
the kidneys and spleen (Image 2.1). GRFT appeared to be most concentrated in 
the spleen, with presence also being observable in the liver, kidney, and vaginal 
tissue 120 hour post treatment. GRFTlec• was not detectible in any organ tissue 
tested. 
Hemagglutination activity 
GRFT's hemagglutination activity in guinea pig blood was analyzed. 
Visual inspection of wells containing PHA, PBS, and GRFT were compared (Fig. 
2.2). As expected, PBS did not show any hemagglutination activity. PHA, a 
lectin with known activity, demonstrated hemagglutination activity in the 0.5 
mg/ml (0.3 ~M) to 1 0 ~g/ml (78.1 nM) range. Comparisons between wells 
demonstrated that GRFT possesses hemagglutination activity in guinea pig 
erythrocytes in the 1 mg/ml (41 ~M) to 1 00 ~g/ml (4.1 ~M) range. At 
concentrations below 1 00 ~g/ml, GRFT did not appear to have any significant 
impact upon erythrocyte agglutination. 
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GRFT Concentrations (Serum) 
GRFT Concentrations (Vaginal) 
Figure 2.1 . Concentrations of GRFT in serum and vaginal washes of guinea pigs 
treated with GRFT or PBS. Serum and vaginal washes from PBS and GRFT-
treated Guinea Pigs was analyzed for GRFT presence. Nanomolar 
concentrations of GRFT were detectible in both serum and vaginal wash samples 
at 120 hours after last administration. Bars indicate mean concentrations with 
standard deviation . 
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Image 2.1. Western blot of guinea pig serum to determine persistence of 
GRFT1ec-. Serum from GRFT-treated and GRFT1eC-treated guinea pigs was 
diluted in running buffer and examined for GRFT or GRFT1ec- presence. At both 
24 and 120 hours post cessation of treatment, GRFT was detectible in serum. 
However, at no time point examined was GRFT1ec-detectible. From left, GRFT, 
GRFT1ec-, and two GRFT-treated animal serum samples. Serum from GRFT1ec-
treated animals was run in lanes 5-9. 
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Neutralization Activity (Serum) 
Neutralization Activity (Vaginal Wash) 
Figure 2.2. Analysis of HIV neutralization activity of guinea pig serum and 
vaginal wash samples. HIV pseudovirus neutralization was used to test samples. 
Numbers represent test sample dilution required to reduce luminescence to 50% 
of test wells containing no serum or vaginal wash sample. Dilutions under 20 




Category Day 11 Day 15 
Group 1ai Group 2a Group 1b Group 2b 
N=3 Std. N=5 Std. Sig. N=3 Std. N=5 Std. Sig. 
WBC 4.92 2.43 2.15 0.23 ns 4.35 1.28 2.9 1.36 ns 
NE 2.3 1.46 0.96 0.13 ns 1.67 0.45 1.01 0.42 ns 
LV 2.49 1.11 1.14 0.28 ns 2.6 0.89 1.82 0.99 ns 
MO 0.09 0.1 0.03 0.03 ns 0.07 • 0.03 0.06 0.04 ns 
EO 0.03 0.02 0.02 0.01 ns 0.02 0.02 0.01 0.02 ns 
BA 0 0.01 0 0 ns 0 0 0 0 ns 
RBC 4.3 0.06 4.12 0.18 ns 4.75 0.21 4.37 0.22 ns 
..... 
Hb 12.23 0.64 11.64 0.46 ns 13.1 i 0.46 12.22 0.61 ns 
HCT 38.3 2.31 36.12 1.47 ns 41.57 1.76 39.52 1.94 ns 
MCV 00.'11 <t. 3 87.58 1.29 ns 87.53 1.7 90.4 0.52 * 
MCH 28.43 1.33 28.26 1.52 ns 27.63 0.61 27.96 1.04 ns 
MCHC 31.97 0.25 32.26 1.33 ns 31.5 0.26 30.94 1.11 ns 
ROW 13.83 1.43 12.92 0.7 ns 14.13 0.29 1.".00 u. * 
PLT 595.33 54.31 628.6 44.77 ns 677.33 11.93 659 34.26 ns 
MPV 4.4 1.14 3.92 0.23 ns 3.57 0.12 3.84 0.24 ns 
Normal CBC Values 
WBC NE LV MO EO BA RBC Hb HCT MCV MCH 
6.0-14.0 0.4-6.7 1.9-11.1 0.0-0.7 0.0-1.0 0.0-0.1 4.4-6.0 11.0-15.0 37.0-48.0 77.5-88.5 22.0-28.0 
MCHC RDW PLT MPV 
28.9-32.0 2.4-27.0 380-650 5.0-20.0 
Table 2.1. CBC values for PBS and GRFT-treated guinea pigs. Whole blood 
samples were analyzed. Values are group averages with standard deviation. 
Two significant changes were observable in GRFT treated animals are denoted 
by (*). 
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Day 11 Day 15 
Grp. Grp. Grp. Grp. Grp. Grp. 
1a 2a 3a 1b St 2b 3b 
N=3 Std. N=5 Std. N=5 Std. Sig N=3 d. N=5 Std. N=5 Std. Sig 
ALB 2.0 2.2 2.3 0.2 2.0 0.3 ns 2.4 0.2 2.2 0.3 1.9 0.2 * 
ALK 166.3 36.7 249.2 61.9 207.6 39 ns 146.7 76 255.6 70 217.8 50.0 Ns 
AMY 702.7 123 883.0 201 657.4 75 ns 817.3 81 820.2 141 629.6 75.8 * 
Table 2.2. Select serum chemistry values for PBS, GRFT-treated, and GRFT1ec-
treated guinea pigs. Serum samples were analyzed for the above chemistry 
values. Significant changes were observed in serum albumin and amylase levels 
in GRFT1ec- treated animals, with those animals displaying chemistry values lower 
than controls. 
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Figure 2.3. Mean whole body weight increases during treatment with PBS, 
GRFT, or GRFT1ec-. GRFT, GRFT1ec-, and PBS treated animals were weighed at 
initiation of treatment and at sacrifice. Average percentage weight gain was 
analyzed. Significantly less weight gain was seen in GRFT and GRFT1ec- treated 
groups at 24 hours after treatment completion (day 11). GRFT1ec- treated animals 
continued to display significantly less weight gain at 120 hours after treatment 
completion (day 15). Bars indicate standard deviation, with significance denoted 
by (*). 
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Figure 2.4. Mean organ weight- to-total body weight percentages of treatment 
groups. Organ weights were determined at sacrifice and normalized by total 
animal weight. Analysis showed that no statistically significant differences were 
observed 24 hours post treatments. However, 120 post treatment significant 
differences in organ weights were observed. Bars indicate standard deviation 







Image 2.2. Immunofluorescent imaging of organ tissues to examine distribution 
and persistence of GRFT. Unstained organ tissue slides from 120 hours post 
treatment were probed for GRFT and GRFT1ec- presence using rabbit anti-GRFT 
primary and FITC-conjugated goat anti-rabbit secondary antibodies. GRFT was 
still observable in kidneys, liver, spleen, and vaginal cross sections. Kidney 
images at 400x magnification; all others at 200x magnification. 
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GRFT PHA 
2.7 mg/ml 0.25 mg/ml 
1.35 mg/ml 50llg/ml 
0.5 mg/ml 51lg/ml 
0.25 mg/ml 0.51lg/ml 
50llg/ml 50 ng/ml 
51lg/ml 5 ng/ml 
0.51lg/ml 
50 ng/ml 
5 ng/ml PBS 
0.5 ng/ml 
Image 2.3. Hemagglutination activity of GRFT on guinea pig erythrocytes. 
Hemagglutination activity of GRFT on guinea: pig blood was analyzed. 
Phytohemagglutinin (PHA) was used as a positive control. PBS was used as a 
negative control. Comparison of wells shows that GRFT possesses 
hemagglutination activity in guinea pig blood in the range of 1 mg/ml (20.5I1M) to 
10011g/ml (2 .05 11M). PHA possesses hemagglutination activity in the 0.5mg/ml 
(0.15I1M) to 10 I1g/ml (39 nM) range. 
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CONCLUSIONS AND FUTURE DIRECTIONS 
Griffithsin persists in serum and maintains strong anti-viral activity while 
simultaneously inducing few systemic changes - an increase in MCV, ROW, and 
spleenomegaly -but displaying no treatment associated organ pathologies. 
Nonetheless, GRFT does have observable hemagluttination activity in guinea pig 
blood within the range of treatment doses. This activity may cause the red blood 
cell variations seen in GRFT treated animals and may account for the 
splenomegaly observed due to an increase in red blood cell turnover. However, 
it is currently unclear whether these effects will be observed in other species. 
Furthermore, in addition to it serum stability and retained anti-viral activity, GRFT 
shows a wide distribution into organs and vaginal mucosal tissues. These 
properties support the further examination of GRFT as a potential systemic anti-
viral therapy for HIV. Additionally, the translocation into vaginal mucosa may 
indicate a potential use for GRFT as a pre-exposure prophylactic measure given 
that GRFT can penetrate into vaginal transudate, which is typically low in protein 
content. 
Previous studies have indicated that while weakly immunogenic, an 
antibody response to GRFT is possible as a result of chronic dosing. However, it 
is unclear what impact an antibody response will have upon GRFT's serum 
persistence, anti-viral activity, and systemic tolerance. We will evaluate the 
effects of immune activation upon active GRFT serum levels and systemic 
tolerance utilizing rat and mouse models. We will also generate serum 
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thermograms of pre-immunized, passively immunized, and chronically exposed 
animals to assess antibody response impacts on serum protein interactions. 
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CHAPTER 3 
CHARACTERIZATION OF BIOCHEMICAL INTERACTIONS OF GRFT BY 
EXAMINING ITS IMPACT UPON SERUM PROTEIN PROFILES AND GRFT-
PROTEASE INTERACTIONS 
INTRODUCTION 
In this chapter we examine biochemical interactions that GRFT may have 
within a living system. We used Differential Scanning Calorimetry (DSC) to 
evaluate the interactions between GRFT and serum proteins in serum from 
guinea pigs treated as outlined in Chapter 2. We also characterized human 
serum spiked with GRFT. Given that GRFT persists in serum and remains active 
after systemic administration, we tested the drug against a panel of biologically 
relevant proteases to fully understand GRFT's proteolytic resistance and to 
characterize potential degradation and metabolic pathways. Finally, we initiated 
experiments using co-immunoprecipitation of GRFT in serum to identify potential 
endogenous binding partners. 
One method that has been applied to explore biochemical binding 
interactions in serum or plasma is Differential Scanning Calorimetry (DSC). 
Plasma consists of over 3000 different proteins but most are present in extremely 
low abundance with 99% of plasma's proteomic mass consisting of 22 proteins 
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[94-95]. DSC has been used to measure the denaturation profile, known as a 
thermogram, of the most abundant proteins present in plasma for healthy 
individuals as well as those suffering from a number of different diseases [96]. It 
has been demonstrated that significant differences are apparent between the 
healthy and disease thermograms presenting the potential for use of this 
method in the clinical diagnosis of diverse disease states such as rheumatoid 
arthritis, lupus erythematosis, and Lyme disease [96-100]. The changes in the 
disease thermogram are proposed to be a manifestation of the interactome 
hypothesis where low molecular weight proteins or peptides unique to a disease 
state bind to the more abundant plasma proteins and alter normal interactions 
between them [101]. DSC is extremely sensitive to changes in concentration of 
protein components in a mixture as well as to binding interactions between 
components making this a powerful technique to probe perturbations in the 
plasma interactome [102]. Measuring a small protein's impact on the more 
abundant plasma proteins can provide invaluable data to describe stabilizing and 
destabilizing effects that a protein may have when introduced into a system. 
Mechanistically, DSC measures small differences in heat flow from a sample and 
a reference chamber as both chambers are heated at a constant rate over a 
temperature range of interest [95, 97]. Differences in heat flow as a consequence 
of thermal events occurring in the sample cell provide a characteristic curve, or 
thermogram, in the form of excess heat capacity of the sample as a function of 
temperature [102]. Every protein has a characteristic denaturation thermogram 
reflecting a unique thermodynamic signature for the melting of the tertiary 
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structure of that protein [100]. For a mixture of proteins, such as plasma, the 
thermogram reflects the superposition of the denaturation thermograms of the 
major protein components according to their relative concentration and the 
presence of any binding interactions [100]. Observation of changes in the plasma 
thermogram as a consequence of binding allows the quantification of binding 
interactions through comparative shifts in denaturation temperatures of the major 
plasma proteins [102]. For example, a protein ligand which prefers the denatured 
state of a larger protein will result in a decrease in the denaturation temperature 
of the larger protein once bound [96]. Thus, it is possible that a consistent and 
significant change in a serum thermogram may be predictive of toxicity 
associated with systemic treatment of GRFT by virtue of it is impact upon normal 
interactions between endogenous serum proteins. 
In addition to DSC thermograms generated, it was also necessary to 
investigate GRFT's resistance to proteolysis. In particular, given its presence in 
vaginal mucosa following systemic administration, GRFT's resistance to a 
number of proteases in the Kallikrein family was evaluated. The Kallikrein family 
of proteases are present in blood, vaginal secretions, and semen [103-104]. 
Furthermore, given GRFT's strong serum persistence, proteases such as 
Trypsin, MMP-12, and elastase were also evaluated given their strong proteolytic 
activity and systemic presence. 
Finally, we began to examine whether potential endogenous binding 
partners of GRFT were responsible for its long serum persistence. In particular, 
hemagluttination assays in species other than guinea pigs were conducted to 
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expand upon the assays outlined and conducted in Chapter 2. Co-
immunoprecipitation of GRFT that had been incubated in serum was used to 
assess whether there are any endogenous binding partners for GRFT that can 
be retrieved from serum. 
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MATERIALS AND METHODS 
DSC- Guinea Pig Serum Profiles 
Serum samples harvested from guinea pigs injected subcutaneously with 
PBS, GRFT, or GRFT1ec- were aliquotted and subjected to DSC analysis. 
Samples were dialyzed into 20mM potassium phosphate, 300mM sodium 
chloride, and 30mM sodium citrate for four days with four buffer changes. Buffer 
pH was adjusted to 7.5 by the addition of sodium hydroxide solution. Following 
dialysis, serum samples were diluted in dialysis buffer (1 :25) and excess specific 
heat readings at temperature ranges from 45°C to 90°C were determined using a 
differential scanning calorimeter (MicroCal VP-Capillary DSC; Instrument 
software: VPViewer 2000 v.2.0.53). Duplicate runs were completed and average 
values for each sample were generated. Total protein concentrations were 
determined via BCA and BGG assays and the concentrations determined were 
used to normalize DSC readings. 
DSC-Human Serum Profiles 
For generation of human serum thermogram profiles, dialysis buffer was 
formulated as before and 3 ml of pooled human serum was dialyzed for a period 
of four days at 4C. Following dialysis, serum was filtered through a 0.45 micron 
filter and 99 ~I aliquots were made for spiking with GRFT, GRFT1ec-, or PBS. 
Dialysis buffer, to serve as a reference, was sterile filtered and stored at 4°C. 
GRFT and GRFT1ec- dilutions in PBS were prepared ranging from 20,000 nM to 
100 nM. Dialyzed serum aliquots were spiked with GRFT, GRFT1ec-, or PBS by 
the addition of 1 ~I of GRFT dilution to the 99 ~I of dialyzed serum. The resulting 
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final concentrations ranged from 1 nM to 200nM, respectively to cover the ranges 
of GRFT concentrations observed in guinea pig serum after subcutaneous 
dosing. Spiked serum samples were diluted in dialysis buffer (1 :25) and excess 
specific heat readings at temperature ranges from 45°C to 90°C were determined 
using a differential scanning calorimeter. As before, BCA and BGG assays were 
conducted and total protein concentrations were used to normalize thermogram 
readings. 
Protease Resistance 
GRFT's resistance to proteolytic degradation was evaluated using a 
number of proteases of the Kallikrein family known to be present in blood, 
seminal fluid and vaginal fluid. Recombinant Kallikrein proteases 3,5,7, 11, 12, 
and 13 (R&D Systems) were reconstituted and activated according to 
manufacturer recommended activation protocols. In addition to Kallikrein 
proteases, MMP-12 (R&D Systems), neutrophil elastase (Sigma), and Trypsin 
(R&D) were also chosen for evaluation. All proteases were reconstituted and 
activated, if necessary, per manufacturer's instructions. 
To approximate both vaginal and seminal fluid environments, vaginal and 
seminal simulant fluids were formulated according to Owen and Katz [105-106]. 
In both vaginal and seminal simulant solutions, BSA was omitted in order to 
avoid potential quenching activity by the BSA. Vaginal simulant solution pH was 
adjusted by the addition of HCL. Sodium hydroxide solution was used to adjust 
the pH of the seminal fluid simulant. 
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In addition to seminal and vaginal fluid simulants, assay buffers were 
prepared according to the manufacturer's directions to serve as optimal activity 
conditions for each protease. For neutrophil elastase, a buffer of 50 mM ACES 
buffer pH 7.2 with 50 11M CalMg was used for optimal activity conditions 
To test GRFT's proteolytic resistance, 2.5 III of GRFT (5.4 mg/ml) was 
combined with 20 III of activated protease and 17.5 III of either optimal activity 
buffer, seminal fluid stimulant, or vaginal fluid simulant. After addition of GRFT, 
samples were vortexed and split evenly between two Eppendorf tubes and 
incubated for either 1 or 6 hours at 3]oC. Ten microliter (10 Ill) aliquots of 
protease mixture in optimized assay buffer were analyzed by mass spectrometry 
by direct infusion of the mixture into the instrument. Remaining samples for all 
proteases were analyzed by either SDS-PAGE or Western blot to assess GRFT 
degradation. Degradation was considered positive if there were a loss or 
substantial decrease in intensity of the GRFT 12.5 kD protein band or if 
deconvoluted mass spectra showed appearance of degradation products. 
Hemagglutination 
GRFT's hemagglutination activity in other species aside from guinea pig 
was analyzed. To test GRFT's hemagglutination activity, human, mouse, and 
sheep erythrocytes (Innovative Research) were washed with PBS to remove cell 
degradation and lysis products. Cells were spun down at 1000 x g for one minute 
and resuspended at a final concentration of 2% in PBS containing 3 giL BSA and 
1 giL sodium azide. Serial dilutions of either Phytohemagglutinin (PHA) (positive 
control) or GRFT were mixed with an equal volume of erythrocytes in a 96 well 
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round bottom plate (total 100 IlUwell) and incubated for 1 hr at room 
temperature, followed by overnight at 4°C. Plates were then allowed to dry. 
Hemagglutination activity was determined by examination of erythrocyte 
aggregation or dissemination in comparison to positive and negative control 
wells. Positive hemagglutination activity was indicated by diffuse blood cells 
along the bottom of the dried plate, denoting formation of a lattice structure due 
to agglutination of multiple erythrocytes. Negative hemagglutination activity was 
observed as a single dot on the bottom of the well, indicating no cell cross-
linking. 
Co-Immunoprecipitation of GRFT from human serum 
Indirect co-immunoprecipitation of GRFT binding ligands in human serum 
was performed using Dynabeads. Briefly, Dynabeads coated with sheep anti-
rabbit IgG were used to precipitate rabbit anti-GRFT antibodies that were either 
incubated with human serum containing GRFT or pre-coated with GRFT. 
4.5 ml human serum (Innovative Research) was aliquotted into 15 ml 
tubes. 4.5 ml of PBS was added to each flask to dilute serum for easier 
magnetic separation. Dynabeads at a concentration of 6.7 x 106 beads/ml were 
separated into four- 500 III aliquots. Four test groups were set up for analysis as 
outlined below. 
For test Group A, serum, PBS, and 500 III Dynabeads were combined and 
incubated at 4°C overnight with gentle agitation. For test Group B, 500 III 
Dynabeads was allowed pre-bind to 6 Ilg of rabbit anti-GRFT antibodies for one 
hour at 3rC. After incubation, beads were placed on a magnetic rack for 
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separation and supernatant containing unbound antibodies was removed and 
discarded. Beads were then washed twice PBS. After a final magnetic 
separation, Dynabeads were resuspended in 500 III of PBS and added to serum 
and PBS. 
For test Group C, 500 III of Dynabeads were combined with 6 Ilg of rabbit 
anti-GRFT antibodies and an excess of GRFT (200 Ilg) for one hour at 37°C. As 
before, after incubation, beads were placed on a magnetic rack for separation 
and supernatant containing unbound antibodies and GRFT was removed and 
discarded. Beads were then washed twice PBS. After a final magnetic 
separation, Dynabeads were resuspended in 500 III of PBS and added to serum 
and PBS. 
Finally, for test Group D, 500 III Dynabeads, 200 Ilg GRFT, and 6 Ilg of 
rabbit anti-GRFT antibodies was added to PBS and serum simultaneously to 
avoid pre-binding of any of the proteins and antibodies. 
All test groups were incubated overnight at 4°C with rotation to facilitate 
protein binding. After overnight incubation at 4°C, Dynabeads were separated 
from the samples via magnetic separation. Supernatant was removed via pipette 
and beads were resuspended in 8 ml PBS for washing. Beads and PBS were 
mixed for two minutes by gentle rocking of the test tube. After thorough mixing, 
tubes were placed on a magnetic rack for separation and the supernatant was 
removed and discarded. The washing process was repeated with an additional 8 
ml of PBS and samples were prepared for protein elution. 
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Elution of the isolated rabbit anti-GRFT antibody, GRFT, and GRFT-
protein complexes were performed via pH shift to denature the bead bound 
antibodies. Briefly, 75 III of 0.1 M citrate buffer of a pH of 2.7 was added to 
immobilized beads. Samples were gently mixed via pipetting for two minutes. 
Following mixing, tubes were placed on a magnetic strip and the supernatant 
containing Ig, GRFT, and protein complexes was transferred to an Eppendorf 
tube. The elution process was repeated with an additional 75 III of citrate buffer 
and samples from both elutions were combined. GRFT and protein presence in 
eluates was examined via SDS-PAGE and Western blot. Eluates were also 
subjected to mass spectrometry for analysis and identification of any proteins 
eluted from the co-immunoprecipitation samples. 
For identification by mass spectrometry, protein samples were dried by 
speedvac and dissolved with 8 M urea in 50 mM NH4HC03 (pH 8). Samples were 
then reduced with dithiothreitol, alkylated with iodoacetamide, diluted with 50 mM 
NH4HC03 and digested with trypsin at 3rC overnight. Trypsin digests were 
desalted with C18 spin column (Pierce, Rockford, IL) and concentrated by 
speedvac. Concentrated samples were then loaded on to a C18 Il-Precolumn 
Cartridge from Dionex (Sunnyvale, CA) and peptides in the samples were 
separated with a packed C18 capillary column with an acetonitrile and 0.1 % 
formic acid gradient by a nanoAcquity LC system. The eluted peptides were 
directed to a L TO Orbitrap XL mass spectrometer (Thermo Fisher Scientific, San 
Jose, CA) via a nanospray source and MS/MS spectra of the peptides were 
acquired by data dependent scan with mass resolution of 100,000 and 7,500 in 
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MS and MS/MS mode respectively. The database search was performed by 
Proteome Discoverer 1.2 from Thermo Fisher Scientific with SEQUEST algorism 
and SwissProt database (Feb 8, 2011). Only proteins with minimum of 2 
distinguish high confident peptide matches (XCorr score 1.9, 2.3 and 2.6 for 




DSC- Guinea Pig Serum Thermograms 
Serum from guinea pigs treated with GRFT and GRFT1ec- displayed a 
substantial shift in excess specific heat capacity versus control animals treated 
with PBS (Figure 3.1). Group member thermograms were averaged and excess 
specific heat capacity was plotted against temperature. Groups 2a and 3a (24 
hours after last treatment) displayed the greatest increase in excess specific heat 
capacity, with Groups 2b and 3b (120 hours after last treatment) continuing to 
display a discernable increase in excess specific heat capacity. GRFT or 
GRFT1ec- treated groups also displayed a nominal increase in the temperature at 
which the serum thermograms peaked. However, comparisons between time 
points demonstrated that as GRFT or GRFT1ec- concentrations decreased in 
serum, average serum thermograms began to approach values obtained from 
PBS treated control groups. 
DSC- GRFT and GRFT1ec- spiked human serum 
Human sera spiked with varying concentrations of GRFT did not display a 
substantial shift in thermograms versus PBS-spiked control serum. (Figure 3.2). 
Furthermore, at all concentrations tested, with the exception of 100 nM GRFT, 
GRFT spiked serum showed a minor decrease in excess specific heat capacity in 
the first peak of the serum thermogram. 
Human sera spiked with varying concentrations of GRFT1ec- also did not 
display a general shift in serum thermograms profiles versus PBS-spiked control 
serum. (Figure 3.3). However, at 1 nM concentrations of GRFT1ec-, there appears 
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to be a greater magnitude of decrease in excess specific heat capacity as 
compared to other molarities. Nonetheless, visual comparisons between GRFT 
and GRFT1ec- spiked groups did not display any characteristic differences in 
serum thermogram profiles between the groups. 
Protease Resistance 
GRFT was resistant to all proteases tested, under all assay conditions, 
and at all time points tested. Six-hour incubations of GRFT with various kallikrein 
proteases and MMP-12 in optimized protease activity buffers was visualized 
using SOS-PAGE analysis with Coomassie blue staining (Image 3.1). 
Comparisons between the GRFT standard and the GRFT present in protease 
incubated samples does not reveal any substantial degradation or decrease in 
intensity of the GRFT band. These results were also observed samples 
incubated in vaginal and seminal simulant fluids at both 1 hour and 6 hours. 
GRFT resistance to all proteases tested was also confirmed via mass 
spectrometry. Selected deconvoluted spectra from GRFT incubated with 
proteases are shown in Figure 3.4. A GRFT -only control was used to determine 
typical fragmentation. Analysis of deconvoluted spectra from samples incubated 
in optimized protease activity buffers did not reveal substantial GRFT 
degradation at any time point tested. 
Hemagglutination 
GRFT's hemagglutination activity in sheep, human, and mouse blood was 
analyzed (Image 3.2). Visual inspection of wells containing suspended blood 
samples, PHA, PBS, and GRFT were conducted. As expected, PBS did not 
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exhibit any hemagglutination activity in any species. PHA, a lectin with known 
hemagglutination activity, demonstrated activity in the 0.5 mg/ml to 10 Ilg/ml 
range (0.3IlM to 78.1 nM range). Comparisons between wells demonstrated that 
GRFT did not possess hemagglutination activity in human, sheep, or mouse 
samples (mouse samples not shown) at any of the GRFT concentrations tested. 
Co-Immunoprecipitation of GRFT from Human Serum 
Co-Immunoprecipitation of GRFT/serum complexes was moderately 
successful. GRFT was captured from serum using the method described above, 
but at substantially less quantities than expected. Western blot analysis of co-
immunoprecipitation eluates demonstrated that groups C and 0 recovered 
detectable amounts of GRFT from serum incubations. Mass spectrometric 
analysis of the eluates revealed a number of proteins were retrieved from the 
serum by the various groups (Figure 3.5). After eliminating kertinocyte related 
proteins and proteins retrieved by non-GRFT bound beads, a number of 
candidate binding partners were identified. 
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Figure 3.1. Mean serum thermograms of guinea pig groups treated with PBS, 
GRFT, or GRFT1ec-. Excess specific heat capacity of guinea pig serum averaged 
amongst groups was plotted against temperature to generate serum 
thermograms. As compared against control groups 1 a and 1 b, GRFT and 
GRFT1ec- treated animals displayed an overall increase in excess specific heat 
capacity as well as a small increase in temperature peak. Intra-group 
comparisons of GRFT and GRFT1ec- treatment groups show a decrease in 































Human Serum Thermogram (GRFT-Spiked) 
-PBS 
- GRFT - 1nM 
- GRFT - 50nM 
- GRFT - 100nM 
- GRFT - 200nM 
55 60 65 70 75 80 
Temperature (OC) 
Figure 3.2. Thermogram of human serum spiked with varying concentrations of 
GRFT. Human serum was spiked with varying concentrations of GRFT and 
excess specific heat capacity was plotted against temperature to generate 
thermograms. Spiking of serum with GRFT at the concentrations listed above 
did not result in substantial changes in serum thermograms. Only one spiking 
group, 100nM GRFT, showed a nominal increase in excess specific heat 




























Human Serum Thermogram (GRFTlec--Spiked) 
-PBS 
- GRFTLec- InM 
- GRFTlec- 50nM 
- GRFTlec- lOOnM 
- GRFTlec- 200nM 
55 60 65 70 75 80 
Temperature (OC) 
Figure 3.3. Thermogram of human serum spiked with varying concentrations of 
GRFT1ec-. Human serum was spiked with varying concentrations of GRFT1ec- and 
excess specific heat capacity was plotted against temperature to generate 
thermograms. Spiking of serum with GRFT at the concentrations listed above 
did not result in an increase in excess specific heat. However, at 1 nM 
concentrations of GRFT1ec-, serum samples appeared to have a decrease in 






Image 3.1. SOS-PAGE gel of six-hour incubations of GRFT with various 
proteases. GRFT was exposed to different proteases and incubated for 6 hours 
in optimized protease activity buffers. GRFT did not display any significant 
degradation from any of the proteases tested. 
60 
12733.1185 
12732.1012 100 100 
Q) 
1 t.l , c Trypsin ro j 
-0 
c GRFT ::l 
.c 







0 0 T .~ I 
11800 13400 12400 13200 
12733.1162 









ro 50 I Q) 
> j ~ , 1 
Qi I 0::: j 1 13147.3220 
1 , II I 0 ; 0 
10000 14000 11800 13200 
12733.1179 100 12733.1172 100 
1 l 
Q) 
t.l KK11 c 
ro 
-0 KK12 c 
::l 
.c 50 I 50 ro 
Q) 1 ; > ~ 1 Qi 
1 
0::: 1 
13147.3245 I l 13147.3209 
-"IIll l l L 0 o ' 
11800 13200 11800 13200 
m/z m/z 
Figure 3.4. Selected mass spectra of GRFT digestions. Six-hour incubations of 
GRFT with proteases in optimized activity buffers were analyzed by mass 
spectrometry. Deconvoluted mass spectrometry analysis of directly infused 





































Image 3.2. Hemagglutination activity of GRFT on human and sheep 
erythrocytes. Hemagglutination activity of GRFT on human and sheep 
erythrocytes was analyzed. Phytohemagglutinin (PHA) was used as a positive 
control. PBS was used as a negative control. Comparison of wells shows that 
GRFT did not display Hemagglutination activity on either sheep or human blood 
in any of the ranges tested. 
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Unique Human Co-IP Products 
Group C Group D 
(GRFT pre-bound to Dynabeads) (GRFT, not pre-bound to Dynabeads) 
14-3-3 protein sigma ~polipoprotein E 
14-3-3 protein zeta/delta ~ttractin 
~ctin, cytoplasmic Complement C4-~ 
~polipoprotein E Plasminogen 
Complement C4-~ 
Heat shock 70 kDa protein 1 Al1 B 
Heat shock protein beta-1 
Putative annexin A2-like protein 
Serotransferri n 
Figure 3.5. Human serum proteins acquired via GRFT co-immunoprecipitation 
using Dynabeads. Co-Immunoprecipitation products for groups A, B, C, and 0 
were analyzed. Control Groups A and B products were non-specific binding 
products of Dynabeads or polyclonal rabbit anti-GRFT antibodies. The table 
above represents the final products of Groups C and 0, after excluding non-
specific protein binding and keratinocyte related proteins. 
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CONCLUSIONS AND FUTURE DIRECTIONS 
esc 
Systemic administration of GRFT may result in changes in serum 
thermograms that are not observable in GRFT-spiked serum. Given the changes 
observed in guinea pig serum of treated animals versus controls, GRFT 
administration may be having some impact on either the serum interactome or 
inducing changes in major serum protein components. Furthermore, in contrast 
to serum thermogram changes observed in GRFT and GRFT1ec- treated guinea 
pigs, spiking of human serum with GRFT and GRFT1ec- did not result in a 
substantial shift in serum thermogram profiles. As such, it is currently unknown 
whether the difference in thermogram shift results is a product of inter-species 
differences, changes in serum proteins, or changes in protein interactions. 
Further experiments are required in order to determine GRFT's impacts upon 
serum thermograms as well as to identify potential endogenous binding partners. 
Proteolytic Resistance 
GRFT has displayed a strong proteolytic resistance to all proteases 
tested. Accordingly, GRFT continues to be a strong candidate for systemic 
administration given that it remains active when exposed to diverse proteases 
that it may encounter both in vaginal tissues as well as in systemic circulation. 
Co-immunoprecipitation 
GRFT is immunoprecipitated from human serum by use of anti-GRFT 
antibodies. Additionally, potential serum binding partners of GRFT were able to 
be isolated and identified by co-immunoprecipitation and mass spectrometry. 
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However, refinement of the immunoprecipitation protocols is needed to increase 
the efficiency of the GRFT-protein complex extractions. First, experiments are 
needed to determine whether the GRFT precipitated from serum is free GRFT 
that isn't bound to any serum partner. Further, there also exists the possibility 
that the serum proteins to which GRFT may bind are of such a low quantity that 
efficient detection and identification will require large amounts of serum to be 
precipitated. Accordingly optimization of precipitation protocols will be essential 
in definitively establishing identities of potential serum binding partners for GRFT. 
Additionally, the difference in Co-IP products between GRFT pre-bound 
and GRFT non pre-bound elutions after elimination of non-specific binding 
products raises the possibility of stearic inaccessibility of GRFT once bound to 
certain proteins. Given that the GRFT pre-bound to beads yielded a greater 
number of proteins, it would appear that this method would likely provide the 
greatest source of binding information. However, we cannot exclude the 
possibility that binding of GRFT to a protein hides the epitopes recognized by the 
antibodies. Interestingly, the presence of apoliprotein E in both samples may 
provide an indication of why GRFT administration resulted in less weight gain 
during treatment than PBS treated controls. Given apoliprotein E's role in lipid 
catabolism, there may be some unseen disruption in this process. However, we 
cannot rule out the possibility of some inflammatory reaction to the presence of 




In the future, we shall conduct guinea pig and human serum spiking 
experiments using a greater range of concentrations of GRFT to determine 
whether thermogram shifts are a result of endogenous serum protein binding, or 
a currently unrecognized biological toxicity. Additionally, using Differential 
Scanning Calorimetry, we shall investigate the thermodynamic impact of 
systemic GRFT treatment, as well as GRFT and GRFT1ec- spiking, upon serum to 
characterize GRFT's impact upon the serum interactome. Further, using 2D gel 
electrophoresis and commercially available multiplex immunoassays, we intend 
to examine changes in serum proteins, cytokines, chemokines and other 
biomarkers resulting from GRFT treatment in rats and mice to determine whether 
any observable changes are a result of drug presence or a result of endogenous 
protein binding. 
Additionally, using co-immunoprecipitation of GRFT in Human serum, we 
shall attempt to catalogue potential endogenous binding partners of GRFT. 
Using mass spectrometry, we shall identify endogenous binding partners as well 




ANALYSIS OF GRFT RESISTANT HIV STRAIN AND GENERATION OF HIV-
ENV PSEUDOVIRUS TO DETERMINE GRFT NEUTRALIZATION CAPCACITY 
INTRODUCTION 
The ability of antiviral and antimicrobial agents to neutralize HIV has been 
measured through the use of pseudovirus technology [93, 107-108]. Providing 
many advantages over handling of live HIV particles, Env pseudovirus 
technology allows for greater reproducibility and precision, as well as allows for 
the analysis of relative infectivity of individual envelope isolates. 
Briefly, 293FT cells, derived from human embryonic kidneys and 
transformed with the SV40 T antigen, are used to produce high titer lentiviruses 
due to their high transfectability. Conventionally, two plasm ids are used for 
transfection and pseudovirus production. The first plasmid possesses genes 
encoding the viral backbone and Tat-genes, but lacking the env gene of HIV. 
The second plasmid possesses the desired env genes. Co-transfection of the 
293FT cells with both plasm ids results in the production of pseudovirions that 
possess envelopes capable of infecting target cells expressing CD4 and the 
CXCR4 and CCR5 co-receptors, but unable to replicate. 
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Once produced, pseudovirus particle titers are determined through the 
usage of TZM-bl cells. TZM-bl cells are HeLa cells which have been engineered 
to express CD4 and CCR5 in addition to expressing their already present CXCR4 
receptors[109]. As such, they are permissive to infection by a wide variety of HIV 
strains, including HIV, SIV, and Env-pseudotyped viruses. In addition to 
presenting necessary receptors for infection, this cell line has also been further 
engineered to contain Tat-responsive reporter genes for luciferase and B-
galactosidase [110]. 
Upon successful infection of TZM-bl cells by env-pseudotyped particles, 
the Tat gene contained on the env-minus plasmid is delivered into the TZM-bl 
cells, inducing an increase in the production of luciferase. Relative infectivity, as 
well as neutralization capacity of various drugs, can thus be measured as a 
function of luciferase gene expression in the presence of luciferase substrate. As 
such, it is a useful mechanism for examining the effectiveness of agents which 
can prevent viral infection since successful infection by the pseudovirus particle 
will result in an increase in chemiluminescence. 
As such, studies into the ability of GRFT to prevent TZM-bl cell infection 
with Env-pseudotyped particles can provide an important tool in examining the 
gp120 spike of HIV, a necessary structure for successful infection. Via site 
directed mutagenesis, changes to the env encoding genes can be made that 
alter potential N-linked Glycosylation Sites (NLGS). Given antiviral activity GRFT 
demonstrates through its binding to the high-mannose glycans attached to these 
68 
NLGS, the impact of NLGS changes on GRFT's effectiveness can be evaluated 
and quantitated. 
In this chapter we will examine the glycosylation states of Du156.12, an 
HIV isolate that is susceptible to neutralization by GRFT, as well as Du156.R18, 
an HIV isolate which has acquired resistance to GRFT neutralization. Finally, we 
will describe the production and optimization of HIV env-pseudoviruses that will 
be used to measure a GRFT neutralization capacity in future experiments 
wherein antibody responses to GRFT are elicited. 
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MATERIALS AND METHODS 
Gene Sequencing of Du156.12 and Du156.R18 
Plasmids of HIV env were supplied by Dr. Montefiori of Duke University. 
Plasmids containing gp120 and gp41 sequences (cloned into pcDNA3.1) from 
strains Du156.12 and Du156.R18 (a GRFT-resistant strain of HIV) were provided 
for analysis and comparison. Competent dh5-alpha bacteria were transformed 
with the appropriate plasmid containing either Du156.12 or Du156.R18 sequence 
strands. After transformation, transformed bacterial colonies were isolated by 
streaking on a plate containing ampicillin for selection. After 12 hours of growth, 
four (4) colonies from each strain were selected and grown in LB broth overnight 
at 37C with vigorous shaking. Du156.12 and Du156.R18 env plasm ids were 
then extracted from bacterial cultures via Miniprep (Quiagen) kit per the 
manufacturer's instructions. 
Aliquots of plasmid preparations containing forward and reverse primers 
for gp120 and gp41 were sent for sequencing. Eleven (11) primers were used 
for sequence generation (Table 4.1). Sequencing results were aligned and 
consensus sequences were generated on Sequencher 4.8 software. 
Pseudovirus generation 
Pseudovirus particles for HIV-env neutralization assays were generated 
using modified methods previously described [93]. Briefly, 293 FT cells were 
cultured for transfection with HIV-env containing plasm ids. Eighteen (18) hours 
before transfection, cells were plated at a density of 6x1 06 . On the day of 
transfection, cells were visually inspected and were 50% confluent. Transfection 
70 
media was prepared by combining120 III of Fugene HO, 12 Ilg of endotoxin free 
Ou156.12 plasmid, and 48 Ilg of pSG3 plasmid in 480 III of OMEM. After mixing, 
the media was allowed to react at room temperature for 30 minutes. At the end 
of 30 minutes, the reaction mixture was added in a drop-wise manner to plated 
293FT cells with gentle swirling of the cell culture plate. 
Plates of transfected cells were allowed to incubate at 3]DC for a period of 
5 hours. At the end of 5 hours, transfection media was removed and replaced 
with fresh media. Transfected cells were placed in a 32°C incubator with 5% C02 
and allowed to incubate for a period of 72 hours. At the end of 72 hours, media 
containing pseudovirus particles was collected, centrifuged at 1000 x g for 15 
minutes, and aliquotted for pseudovirus titration. 
Pseudovirus Titration 
Titration of media containing pseudovirus particles was conducted via 
titration in TZM-bl cells to probe for changes luciferase expression due to 
successful infection with pseudovirus particles containing the luciferase promoter 
gene. Briefly, serial dilutions of pseudovirus stock ranging from undiluted to a 
dilution of 1 :78125 were placed into 96-well white tissue culture plates, by 
addition of pseudovirus stocks to wells containing 100 III of media (OMEM with 
10% FBS - no phenol red) in all wells. 100 III of TZM-bl cells at a density of 
100,000 cells/ml in media (OMEM with 10% FBS- no phenol red) were added to 
all wells and incubated at 3]DC for 72 hours. Cells only wells, containing no 
pseudovirus stock were used as background-Iuciferase production controls. At 
the end of 72 hours, culture media was removed and the cells were gently 
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washed by the addition of 200 ~I of PBS. PBS was removed and cells were 
lysed by addition of 50 ~I of room temperature lysis buffer and 30 minutes of 
vigorous shaking. Luciferase detection reagent was prepared by dissolving the 
luciferase assay substrate in 10 mL of luciferase assay buffer. After cells were 
lysed, luciferase activity was measured by the addition of 1 00 ~I of luciferase 




Gene Sequencing of Du156.12 and Du156.R18 
Sequencing of Du156.12 and Du156.r18 revealed a number of 
glycosylation changes in the Du 156.r18 gp120 sequence that resulted in four 
glycosylation site deletions and one glycosylation site addition (Figure 4.1). Two 
glycosylation site deletions, one at the beginning of the V3 domain and one 
between the V4 and V5 domains were the result of base changes which resulted 
in the Asn-X-SerfThr sequon being eliminated. Namely, the sequon deletion at 
the beginning of the V3 domain of Du 156. R 18 was the result of an Asparagine 
being substituted with a Serine residue. The sequon deleted between V4 and V5 
was the result of a Threonine being substituted with an Isoleucine residue in the 
N-X-T sequon. 
However, residue substitution was not the only mechanism by which 
Du156.R18 modified its NLGS. Two of the four potential N-linked glycosylation 
site deletions were the result of a 30 amino acid deletion in the V1/V2 loop, which 
resulted in a shortening of the V1N2 loop by 10 residues. In contrast to the 
glycosylation site deletions, there was the addition of one glycosylation site at 
residues 341-343 by the substitution of Threonine for Alanine, which resulted in 
the creation of aN-linked glycosylation site sequon. 
Pseudovirus Generation and Titration 
Titration of Pseudovirus particle containing media in TZM-bl cells revealed 
a successful creation of infective Du156.12 pseudoparticles (Figure 4.2). 
Chemiluminescence, expressed in Relative Luminescence Units (RLU) was 
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plotted against virus stock dilution. Titre results showed that undiluted virus 
stocks resulted in an almost 6 fold increase in luciferase expression in TZM-bl 
cells, producing an average RLU of 20448. Furthermore, this increased 
expression was observable at even the lowest viral concentrations tested 
(1 :78125 dilution of virus stocks). Background TZM-blluciferase activity was 
determined to be 3600. 
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Table 4.1. Primers used for Du156 sequencing. The above forward and reverse 
primers were used to generate consensus sequences of plasmids containing 
HIV-env Du156.12 and Du156.R18. 
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Ref: Du156.12 
V1 N2 V3 V4 V5 
III II I I I I I I III I I I I I II I I I 
o 100 200 300 400 460 
Ref: Du156.R18 
V1N2 V3 V4 V5 
I 
III I I I I I I II I 




o 100 200 300 400 450 
Figure 4.1. Potential N-linked glycosylation sites (NLGS) of gp120 of Du156.12 
and Du156.R18. Sequencing analysis of Du156.12 and Du156.R18 revealed a 
number of NLGS changes. Sequons of Asn-X-Ser and Asn-X-Thr, where X ¢Pro 
were recorded. Two (2) NLGS were deleted by removal of 10 amino acid 
residues (SSATYNNSMN) in the V1/V2 loop of Du156.R18. Du156.R18 also 
displayed a deletion of one NLGS in V3, an addition of one NLGS in V4, and a 
deletion of one PNGS near residue 400. Total NLGS for Du156.12 totaled 24, 

















o L-__________________ _ 
Virus Dilution 
~Du156.12 
Figure 4.2. Pseudovirus titre of Du.156.12 in TZM-bl cells. Analysis of 
pseudovirus production in 293FT cells for GRFT neutralization assays 
demonstrated production of infective HIV-env virions. Undiluted samples 
displayed an average chemiluminescence reading of 20448 Relative 
Luminescence Units (RLU). At a 1 :78125 dilution of pseudovirus stocks, 
chemiluminescence was still detectible, with an average rating of 11748 RLU. 
Cells-only background wells displayed an average RLU of 3600. 
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CONCLUSIONS AND FUTURE DIRECTIONS 
Gene Sequencing of Du156.12 and Du156.R18 
Differences in NLGS between DU156.12 and Du156.R18 may be 
responsible for its resistance to GRFT neutralization. With less potential high-
mannose glycans present on gp120, GRFT's ability to impede infection of cells 
may be reduced. However, it is important to note that two of the glycan deletions 
were a result of a 10 residue deletion in the V1N2 region of gp120, thus 
shortening the V1N2 loop while simultaneously eliminated two NLGS. Previous 
studies have shown that a shortened V1N2 loop may result in increased 
infectivity of viral isolates [56-57]. Accordingly, there may be some synergistic 
effect between the loss of NLGS and shortening of the V1 N2 loops which 
promotes viral evasion of GRFT binding while simultaneously allowing closer 
interaction with cellular receptors necessary for viral infection. 
Pseudovirus Generation and Titration 
Pseudovirus particles from the Du156.12 strain of HIV will be a useful 
control for examining GRFT's potential neutralization capacity in other 
experiments, including long term animal dosing. Accordingly, Du156.12 env-
pseudoviruses will be a useful starting point for the induction of NLGS changes to 
observe how GRFT's activity is impacted as NLGS are modified. However, 
further optimization of the pseudovirus production protocol is needed in order to 
increase RLUs even higher above background to increase overall assay 
sensitivity. 
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Once optimized, the use of this HIV-1 pseudovirus technology will enable 
us to fully evaluate the impact that an antibody response will have upon the 
neutralization capacity of GRFT. If continued activity of GRFT is seen in 
pseudovirus assays despite an antibody response, this finding would indicate 
that GRFT treatment may continued even though an antibody response is 
mounted. However, should GRFT become less active after an immune response 
is generated, it may indicate that GRFT's usefulness would be limited to short 
term courses of therapy. 
In the future, it would be prudent determine binding interactions between 
GRFT and modified gp120 glycans. As mentioned before, pseudovirus 
neutralization assays are powerful tools to assess GRFT's neutralization capacity 
versus gp120's possessing modified glycans. Via site-directed mutagenesis, 
potential NLGS's could be eliminated and HIV-env mutations should be tested 
against GRFT concentrations in pseudovirus neutralization assays. Additionally, 
purified gp120-GRFT interactions should be probed using isothermal titration 
calorimetry, analytical ultracentifugation, and protein binding assays to explore 
affinity and avidity interactions between modified gp120s and GRFT in order to 




OVERALL RESEARCH IMPLICATIONS AND APPLICATIONS 
HIV treatment 
The totality of the research presented in this thesis supports GRFT's utility 
as a new adjunct therapy to assist in combating chronic HIV infection. As we 
have demonstrated, GRFT can be maintained in serum at levels far exceeding its 
anti-HIV-1 EC5o. We also showed that GRFT is well tolerated in animals when 
dosed subcutaneously, with little impact upon organ systems, CBC counts, and 
serum chemistries. While hemagglutination assays did demonstrate 
agglutination activity on guinea pig erythrocytes, no such activity was seen in 
human erythrocytes. Thus it is questionable whether some of the systemic 
effects observed in guinea pigs would occur in humans. 
Given the various mechanisms of the various HAART treatment regimens, 
GRFT treatment could provide an additional method of interrupting the infection 
cycle of HIV as well as extending the useful life of current therapies. By 
preventing fusion with cells, GRFT may be useful in reducing infection of 
uninfected cells as well as prolonging the usefulness of other anti-HIV therapies 
by binding to drug resistant escape mutants when viral loads are pushed to 
undetectable levels. This may effectively decrease the speed with which HIV 
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acquires resistance to other HAART drugs by denying drug-resistant escape 
mutants an opportunity to establish a foothold in uninfected cells. 
Further research into the systemic effects in other species will be 
necessary in order to determine whether the tolerability profile observed in 
guinea pigs is consistent among species. Additionally, research into how an 
antibody response will impact GRFT's systemic profile and activity are 
necessary. As a foreign protein capable of generating an immune response, 
GRFT will have to maintain activity in the face of an immune response given that 
immunosuppressive options used to reduce the body's response to a 
proteinacious therapy may not be viable given the nature of HIV infection. 
Prophylaxis 
GRFT translocation into the vaginal mucosa also supports GRFT's utility 
in combating HIV, albeit in a different manner. With GRFT being found present 
in vaginal mucosal washes, systemic GRFT treatment provides the opportunity to 
have GRFT persistently at one of the major portals of infection- the vaginal 
mucosa. Accordingly, GRFT may prove to be a second line protection useful for 
serodiscordant partners should longer term GRFT immunotherapy become a 
viable pre-exposure prophylaxis modality. 
Immunotherapy 
As has been demonstrated before, HIV-1 resistance to GRFT and other 
lectins has entailed the removal of high mannose glycans via alterations in N-
linked glycosylation sites [4, 7, 111]. Burst therapy, the use of the drug over 
short periods of time, may be a way to encourage viral evolution towards the 
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removal of epitope obscuring high-mannose glycans. Accordingly, the favorable 
short term profile that was observed in guinea pigs suggests that should even 
long term treatment with GRFT not be feasible due to potential immune reactions 
or unseen toxicties, GRFT may still be a viable tool in combating HIV. 
Differential Scanning calorimetry. 
Current assays have not demonstrated any toxicities of GRFT. 
Accordingly, novel methods to identify potential toxicities are necessary fully 
understand the impact of adding GRFT into a living system. DSC thermograms 
can be used to measure complex biochemical binding interactions as well as 
provide potential information into biocomparability. The use of DSC to evaluate 
the impact of GRFT therapy may ultimately provide a screening mechanism by 
which to measure potential biological impacts not observable by other methods. 
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APPENDIX 
List of Abbreviations 
GRFT Griffithsin 
HIV Human Immunodeficiency Virus 
HCV Hepatitis C Virus 




ER Endoplasmic Reticulum 
DNA Deoxyribonucleic Acid 
HAART Highly Active Anti Retroviral Therapy 
PBS Phosphate Buffered Saline 
CBC Complete Blood Count 
BSA Bovine Serum Albumin 
SDS Sodium Dodecyl Sulfate 
PAGE Polyacrylamide Gel Electrophoresis 


























Nonfat Dry Milk 






Red Blood Cells 
Hemoglobin 
Hematocrit 
Mean Corpuscular Volume 
Mean Corpuscular Hemoglobin 
Mean Corpuscular Hemoglobin Concentration 
Red Cell Distribution Width 






Analysis of Variance 








Bovine Gamma Globulin 
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